SL’s vaccine status

Sri Lanka’s drug regulator, the National Medicines Regulatory Authority (NMRA), has so far granted emergency-use listing to OxfordAstraZeneca’s CO VI SHIELD manufactured by Serum Institute, India and Sputnik-V manufactured by Gamaleya Research Institute, Russia.

The NMRA, meanwhile, has granted a waiver to the vaccine commonly called Sinopharm manufactured by the state-owned China National Pharmaceutical Group Corporation for the import of a donation of 600,000 doses. This vaccine has been given to 2,469 Chinese workers in Colombo, Puttalam, Kandy and Hambantota between April 2 and 8.

Vaccines received and administered so far –

500,000 doses of COVISHIELD (donation from India) 500,000 doses of COVISHIELD (bought from India)

264,000 doses of COVISHIELD (from COVAX)

Doses administered from January 29 to April 10 – 925,242 Doses remaining from stocks in hand – 338,758

Second doses due between April 23 and May 20 – 393,469 COVAX (the COVID-19 Vaccine Global Access) is a global initiative which works with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines. It is co-led by GAVI (the Vaccine Alliance); CEPI (the Coalition for Epidemic Preparedness Innovation); and WHO (the World Health Organization).